Virtual Oncology

Global Virtual Oncology Market to Reach US$10.2 Billion by 2030

The global market for Virtual Oncology estimated at US$3.9 Billion in the year 2024, is expected to reach US$10.2 Billion by 2030, growing at a CAGR of 17.4% over the analysis period 2024-2030. Software, one of the segments analyzed in the report, is expected to record a 19.2% CAGR and reach US$6.3 Billion by the end of the analysis period. Growth in the Service segment is estimated at 14.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 23.2% CAGR

The Virtual Oncology market in the U.S. is estimated at US$1.1 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.3 Billion by the year 2030 trailing a CAGR of 23.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.7% and 15.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.9% CAGR.

Global "Virtual Oncology" Market – Key Trends & Drivers Summarized

How Is Virtual Oncology Transforming Cancer Care in the Digital Era?
Virtual oncology, the digital extension of traditional cancer care, is redefining how patients access diagnostics, treatment planning, second opinions, and follow-up care without geographic or mobility constraints. At its core, virtual oncology leverages telemedicine platforms, AI-enhanced diagnostics, and remote monitoring tools to deliver personalized cancer care efficiently and equitably. Patients can now consult oncologists across borders, share diagnostic scans via secure portals, and receive expert input on treatment regimens without traveling long distances. This is particularly valuable for rural and underserved populations where oncology specialists and advanced cancer centers are often unavailable. Through virtual tumor boards and multidisciplinary e-consultations, clinicians across institutions collaborate in real-time to develop precise treatment strategies. The COVID-19 pandemic accelerated the adoption of tele-oncology platforms, pushing hospitals and cancer centers to develop secure, HIPAA-compliant systems to manage ongoing cancer therapies virtually. Now, even as physical operations resume, many providers are retaining hybrid care models that blend in-person procedures with virtual consultations, especially for survivorship care, genetic counseling, and routine assessments. The result is a more streamlined, continuous, and patient-centric cancer care model that reduces delays and improves access.

Is AI Becoming the Backbone of Virtual Oncology Services?
Artificial intelligence is emerging as a vital enabler of virtual oncology by enhancing diagnostic accuracy, predicting treatment response, and automating routine clinical workflows. AI-powered imaging platforms are transforming how radiologists detect tumors in CT, MRI, and PET scans with greater precision and speed. These systems can analyze massive datasets to uncover patterns that are often invisible to the human eye, enabling early diagnosis and staging of cancers like lung, breast, and prostate. In pathology, AI algorithms are assisting in the digital analysis of biopsy slides, helping pathologists classify tumor types remotely and consistently. Natural language processing (NLP) tools are being used to extract actionable insights from oncology reports and patient notes, feeding into decision-support systems for oncologists. AI is also powering predictive models that estimate progression risks, adverse drug reactions, and the likely efficacy of targeted therapies — allowing oncologists to tailor treatments in advance. These tools, when integrated into virtual care platforms, enable oncologists to deliver high-quality care from a distance, informed by advanced analytics rather than just subjective assessments. Furthermore, oncology-focused AI chatbots and virtual care assistants are now supporting patients in medication adherence, symptom tracking, and treatment side effect management — all in real-time and without the need for clinic visits.

How Are Patient-Centered Tools Enhancing the Reach of Virtual Oncology?
The rise of digital therapeutics and patient-facing oncology tools is significantly improving how cancer patients engage with and benefit from virtual oncology services. Mobile apps designed for oncology care now offer features like medication reminders, pain and symptom diaries, dietary guidance, and secure messaging with healthcare teams. These tools are particularly important for patients undergoing chemotherapy or immunotherapy, where symptom management between visits can impact survival and quality of life. Wearable biosensors and connected medical devices allow clinicians to remotely monitor vitals such as heart rate, temperature, and oxygen saturation — metrics that can indicate adverse drug reactions or infections in immunocompromised patients. Virtual reality (VR) and augmented reality (AR) applications are emerging as adjuncts for pain distraction, stress relief, and patient education during therapy cycles. Moreover, online peer support groups, virtual counseling, and digital platforms for palliative care are offering psychosocial support to both patients and caregivers, which is an often-overlooked aspect of cancer treatment. The personalization of virtual oncology is further supported by genomics platforms that integrate molecular profiling data into virtual treatment discussions, allowing for more targeted and efficient care plans tailored to each patient’s tumor biology.

What’s Driving the Surge in Global Virtual Oncology Adoption?
The growth in the virtual oncology market is driven by several factors rooted in the evolution of oncology workflows, patient expectations, and healthcare digitization. A key factor is the global increase in cancer incidence, which has overwhelmed traditional cancer care infrastructures, creating a pressing need for scalable digital alternatives. The rapid digitization of oncology data — from radiological images to genomic sequences — has enabled remote analysis and cloud-based collaboration, making it easier for specialists to provide expert opinions from anywhere in the world. Rising healthcare consumerism has also influenced market dynamics, with patients increasingly seeking second opinions and convenience through virtual consultations. In parallel, health systems and insurers are investing in virtual oncology platforms as part of value-based care models, aiming to reduce hospitalizations, improve patient outcomes, and lower overall cancer treatment costs. The integration of EHRs, PACS (Picture Archiving and Communication Systems), and telepathology solutions is making it seamless for cancer centers to transition parts of their workflow into virtual environments. Additionally, reimbursement parity policies and regulatory support in major markets like the U.S., Canada, Germany, and India have made virtual oncology financially viable for providers and patients alike. As personalized medicine and immuno-oncology continue to expand, the complexity of cancer care will require more collaborative, remote, and intelligent systems — all of which are at the heart of the virtual oncology ecosystem.

SCOPE OF STUDY:

The report analyzes the Virtual Oncology market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Component (Software, Service, Hardware); Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer, Bladder Cancer, Other Cancer Types); Application (Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management, Other Applications); End-User (Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations, Other End-Users)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

• Accuray Incorporated
• Amwell (American Well)
• Caris Life Sciences
• Cerner Corporation
• Color Health
• CureMatch, Inc.
• Elekta AB
• Epic Systems Corporation
• Flatiron Health
• Jasper Health
• McKesson Corporation
• OncoHealth
• OncoLens
• OneOncology
• Optum, Inc.
• Philips Healthcare
• Reimagine Care
• Siemens Healthineers
• SimBioSys
• Varian Medical Systems, Inc.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.